Sato, KeisakuBaiocchi, LeonardoKennedy, LindseyZhang, WenjunEkser, BurcinGlaser, ShannonFrancis, HeatherAlpini, Gianfranco2023-01-172023-01-172021-06-01Sato K, Baiocchi L, Kennedy L, et al. Current Advances in Basic and Translational Research of Cholangiocarcinoma. Cancers (Basel). 2021;13(13):3307. Published 2021 Jul 1. doi:10.3390/cancers13133307https://hdl.handle.net/1805/30942Cholangiocarcinoma (CCA) is a type of biliary tract cancer emerging from the biliary tree. CCA is the second most common primary liver cancer after hepatocellular carcinoma and is highly aggressive resulting in poor prognosis and patient survival. Treatment options for CCA patients are limited since early diagnosis is challenging, and the efficacy of chemotherapy or radiotherapy is also limited because CCA is a heterogeneous malignancy. Basic research is important for CCA to establish novel diagnostic testing and more effective therapies. Previous studies have introduced new techniques and methodologies for animal models, in vitro models, and biomarkers. Recent experimental strategies include patient-derived xenograft, syngeneic mouse models, and CCA organoids to mimic heterogeneous CCA characteristics of each patient or three-dimensional cellular architecture in vitro. Recent studies have identified various novel CCA biomarkers, especially non-coding RNAs that were associated with poor prognosis or metastases in CCA patients. This review summarizes current advances and limitations in basic and translational studies of CCA.en-USAttribution 4.0 InternationalBiomarkersCholangiocarcinomaGenetic aberrationsOrganoidsPatient-derived xenograftArticle